There are many ongoing clinical trials using anti-CD19 and anti-BCMA CAR T cells to treat autoimmune diseases including Systemic Lupus Erythematosus (SLE), Myasthenia Gravis, Systemic Sclerosis, Idiopathic Inflammatory Myopathy, and others (5, 6). This evidence concerns the gene CD19 and autoimmune disease.